Compare AEF & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEF | TENX |
|---|---|---|
| Founded | 1989 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 317.8M |
| IPO Year | N/A | 2001 |
| Metric | AEF | TENX |
|---|---|---|
| Price | $9.61 | $10.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 140.7K | ★ 629.4K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.51 | $5.34 |
| 52 Week High | $10.14 | $18.38 |
| Indicator | AEF | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 36.53 |
| Support Level | $6.19 | $10.87 |
| Resistance Level | $9.99 | $14.15 |
| Average True Range (ATR) | 0.25 | 0.70 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 60.30 | 9.75 |
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.